Great news regarding the anti vaccine-Covid of the University of Oxford, Irbm and Astrazeneca. The data from phase 2 of the experimentation bode well on its effectiveness, especially as regards the subjects most at risk of contagion.
University of Oxford Covid vaccine, Irbm and Astrazeneca: the results of phase 2
The results obtained from phase 2 concerning the Coronavirus vaccine of the University of Oxford, Irbm and Astrazeneca are very positive. It appears to be well tolerated, especially in the elderly. It also provides immune-level protection similar to that seen among young adults. The Lancet magazine published the results of the experiment.
The experimentation
The trial was started on 560 healthy adults, of which 240 with an age exceeding 70 years. However, we will still have to wait for the results of phase 3 of the trial (in progress), to find out whether or not it protects against SarsCov2 infection. Some non-scientific journals had already anticipated some data of phase 3. Already at the beginning of October the European Medicines Agency had started the rolling review, that is the first step of the approval process. However, it will now be necessary to confirm the validity of the data obtained. The vaccine, in fact, must meet some basic requirements required by the World Health Organization (WHO).
